Aachen (ots) - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company's Communications department since 2021. In her new position, Maren will oversee Grünenthal's communications operations across all markets and lead the team based at the company's headquarters in Aachen. She will report directly to CEO Gabriel Baertschi.

This appointment comes at a pivotal moment in Grünenthal's transformation, following the company's outstanding financial performance in 2024. Since 2017, Grünenthal's profitability, measured by adjusted EBITDA, has more than tripled, driven by strategic acquisitions and partnerships such as the acquisition of the US company Valinor Pharma and the product Movantik(TM) in July 2024. Additionally, Grünenthal continues to advance its key R&D programs, including progressing the Glucocorticoid Receptor Modulator (GRM) and Nociceptin (NOP) Receptor Agonist programs to the next development stages, along with ongoing progress in its Nav compounds. The company is also focusing on accelerating growth in Qutenza(TM) and its Established Brands, while ensuring a smooth integration of Valinor Pharma and pursuing further strategic acquisitions.

Maren joined Grünenthal in 2021 as Head of Global Commercial Communication and was subsequently the Planning Director for the company's commercial organization. Prior to joining Grünenthal Maren was a Director at FleishmanHillard, one of the world's leading global PR firms.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better - and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of EUR1.8 billion.

More information: https://www.grunenthal.com

Follow us on: LinkedIn: Grunenthal Group (https://www.linkedin.com/company/gruenenthal?originalSubdomain=de)

Instagram: grunenthal (https://www.instagram.com/grunenthal/?hl=de)

Click here for our Grünenthal Report 2024/2025 (https://grunenthal-annualreport24.corporate-report.net/#0)

Contact:
Maren Thurow, Head Global Communications at Grünenthal
maren.thurow@grunenthal.com

Logo

Tags

More Like This

GRÜNENTHAL TAKES FULL OWNERSHIP OF GRÜNENTHAL MEDS, THE JOINT VENTURE ESTABLISHED WITH KYOWA KIRIN FOR ITS ESTABLISHED MEDICINES BRANDS

GRÜNENTHAL STRENGTHENS ITS GENETIC MEDICINE CAPABILITIES AND JOINS THE CLUSTER FOR NUCLEIC ACID THERAPEUTICS MUNICH

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

Stallergenes Greer Announces Appointment of Andreas Amrein as Chief Executive Officer

Gunnar Eberhardt appointed Executive Vice President, UPM Communication Papers and member of the Group Executive Team

Hansa Biopharma announces key executive appointments to support continued growth

Grünenthal Advances Global Regulatory Information Management and Operations with Veeva

Hansa Biopharma appoints Maria Törnsén as Chief Operating Officer and President U.S.